Thank you for your interest in Freyr’s Webinar Series (FWS). The webinar on, “Drug Importation to India- A Regulatory Blueprint,” was successfully concluded on June 17, 2021. Here is an archived version for your perusal.

 

What Was It All About?

In this webinar, our Indian Regulatory experts - Dr Ghulam Moinuddin and Michael Lambell have elaborated:

  • Overview to Indian Pharma Market & CDSCO/DCGI
  • Why India? (potential of pharma business in Indian market)
  • India on Priority: Top 5 Global Pharmaceuticals/Bio-Pharmaceutical MNCs
  • India-Regulatory pathway: Marketing Authorization Approval/Import Permission; Registration of Manufacturing Facility; Import License
  • Clinical Trial Approval
  • Rationale for New Drug Approval and Requirements
  • Authorized Indian Agent and Warehouse: Overview
  • Regulatory Challenges Faced by a New Applicant
  • Success Story

As a continuous practice, Freyr is destined to organize more webinar sessions related to Regulatory aspects of Life Sciences. We presume that you would like to be a part of all those sessions. If yes, let us have an opportunity to inform you about our next session.

Let us notify you